Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 60Breast Neoplasms 54Ovarian Neoplasms 35Triple Negative Breast Neoplasms 28Lung Neoplasms 25Fallopian Tube Neoplasms 24Endometrial Neoplasms 24Neoplasm Metastasis 22Squamous Cell Carcinoma of Head and Neck 19Parkinson Disease 4, Autosomal Dominant Lewy Body 19Neoplasms 15Esophageal Neoplasms 13Esophageal Squamous Cell Carcinoma 12Carcinoma, Ovarian Epithelial 10Stomach Neoplasms 9Head and Neck Neoplasms 9Carcinoma 9Colorectal Neoplasms 8Adenocarcinoma Of Esophagus 7Adenocarcinoma 7Peritoneal Neoplasms 6Uterine Cervical Neoplasms 5Melanoma 5Small Cell Lung Carcinoma 4Oropharyngeal Neoplasms 4Cholangiocarcinoma 4Carcinoma, Transitional Cell 4Urinary Bladder Neoplasms 3Respiratory Tract Neoplasms 3Recurrence 3

Interventions

talimogene laherparepvec 1exemestane 1Tamoxifen 1Surgical Procedures, Operative 1Specimen Handling 1Paclitaxel 1Mastectomy, Segmental 1Letrozole 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ductal × Paclitaxel × 90 days × Clear all
NCT02779855 2026-03-10

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
50 enrolled 12 charts
Breast

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡